After a high-profile breast cancer failure bit into its potential sales, Eli Lilly’s ramucirumab aced a Phase III study in lung cancer, renewing hopes that the star of the drugmaker’s oncology pipeline can still deliver on its promise.

…read more

Source: Lilly heralds a lung cancer victory for blockbuster hopeful ramucirumab


0 No comments